clinic
practic
guidelin
base
evidencebas
medicin
promot
evidencebas
object
effici
medic
practic
numer
evidencebas
clinic
practic
guidelin
also
develop
includ
treatment
guidelin
communityacquir
pneumonia
develop
addit
data
distribut
caus
bacteria
communityacquir
pneumonia
antibiot
resist
obtain
sinc
variou
guidelin
diagnosi
treatment
prevent
pneumonia
also
develop
abroad
therefor
becom
necessari
revis
current
guidelin
commun
acquir
pneumonia
korea
antibiot
resist
recent
rais
seriou
public
health
issu
worldwid
wherea
resist
bacteria
remov
exist
antibiot
increas
number
less
less
novel
antibiot
develop
issu
antibiot
resist
much
seriou
korea
countri
major
caus
bacteria
highest
antibiot
resist
former
worldwid
antibiot
resist
proport
level
antibiot
misus
level
antibiot
use
korea
higher
averag
level
antibiot
use
worldwid
rate
prescrib
antibiot
infect
requir
antibiot
treatment
also
higher
korea
countri
present
clinic
practic
guidelin
provid
revis
recommend
appropri
diagnosi
treatment
prevent
communityacquir
pneumonia
guidelin
may
help
reduc
differ
level
treatment
medic
institut
medic
staff
enabl
effici
treatment
may
also
reduc
antibiot
resist
prevent
antibiot
misus
acut
lower
respiratori
tract
infect
korea
antibiot
treatment
guidelin
develop
committe
lower
respiratori
tract
infect
adult
form
novemb
committe
includ
mani
associ
medic
institut
possibl
committe
member
recommend
korean
societi
chemotherapi
korean
societi
infecti
diseas
korea
academi
tuberculosi
respiratori
diseas
korean
associ
famili
medicin
korean
medic
practition
associ
nation
evidencebas
healthcar
collabor
agenc
particip
develop
guidelin
guidelin
set
forth
fundament
principl
antibiot
use
communityacquir
pneumonia
adult
age
year
older
take
account
current
situat
regard
communityacquir
pneumonia
korea
march
studi
publish
english
last
year
search
ovidmedlin
ovidembas
use
search
foreign
studi
kmbase
koream
use
search
domest
studi
clinic
practic
guidelin
search
ngc
gin
komgi
search
date
februari
level
recommend
divid
strong
weak
level
evid
divid
high
moder
low
low
level
recommend
level
evid
determin
use
unoffici
agre
method
consensu
deem
reach
particip
committe
member
agre
strong
benefit
evid
outweigh
cost
loss
cost
loss
evid
outweigh
benefit
weak
level
evid
low
clear
differ
benefit
loss
high
possibl
level
certainti
estim
valu
effect
chang
futur
studi
low
moder
futur
studi
import
influenc
level
certainti
estim
valu
effect
valu
may
chang
low
futur
studi
highli
like
affect
level
certainti
estim
valu
effect
valu
highli
like
chang
low
effect
estim
certainti
clinic
practic
guidelin
develop
use
adapt
method
first
key
question
kq
includ
guidelin
select
key
question
follow
popul
intervent
comparison
outcom
pico
principl
literatur
search
process
expert
use
systemat
search
equat
search
total
studi
base
content
expert
review
titl
abstract
studi
whose
origin
copi
avail
select
studi
total
four
clinic
practic
guidelin
address
key
question
includ
guidelin
extens
select
qualiti
four
domest
foreign
clinic
practic
guidelin
assess
use
assess
scale
develop
clinic
practic
guidelin
expert
committe
korean
academi
medic
scienc
name
kagre
korean
version
agre
twelv
committe
member
educ
assess
method
workshop
run
expert
assess
select
studi
two
guidelin
british
thorac
societi
bt
guidelin
manag
commun
acquir
pneumonia
adult
updat
guidelinea
manag
adult
lower
respiratori
tract
infect
updat
joint
taskforc
european
respiratori
societi
european
societi
clinic
microbiolog
infecti
diseas
select
review
ultim
total
four
clinic
practic
guidelin
includ
domest
guidelin
publish
consensu
guidelin
manag
communityacquir
pneumonia
adult
publish
infecti
diseas
societi
americaamerican
thorac
societi
idsaat
adapt
target
domest
guidelin
select
adapt
target
guidelin
develop
guidelin
develop
committe
intern
meet
present
spring
academ
confer
held
korean
societi
chemotherapi
korean
societi
infecti
diseas
guidelin
revis
improv
base
discuss
confer
revis
made
base
expert
opinion
gather
public
hear
particip
expert
relat
associ
complet
guidelin
develop
guidelin
develop
use
adapt
method
due
time
limit
although
foreign
clinic
practic
guidelin
guidelin
adapt
schedul
revis
near
futur
present
development
period
could
use
develop
guidelin
guidelin
undergo
minor
revis
soon
revis
version
guidelin
publish
guidelin
also
revis
everi
year
reflect
recent
studi
result
outsid
insid
korea
guidelin
develop
fund
govern
polici
research
project
diseas
control
centr
committe
member
particip
guidelin
develop
influenc
govern
branch
academ
societi
pharmaceut
compani
interest
group
antibiot
treatment
pneumonia
depend
empir
method
sinc
distribut
caus
bacteria
antibiot
resist
vari
countri
necessari
develop
appropri
antibiot
treatment
guidelin
base
domest
epidemiolog
data
guidelin
summar
domest
research
find
caus
bacteria
communityacquir
pneumonia
affect
korean
adult
current
level
antibiot
resist
korea
communityacquir
pneumonia
caus
variou
bacteria
similar
distribut
bacteria
seen
korea
countri
bacteria
streptococcu
pneumonia
haemophilu
influenza
mycoplasma
pneumonia
chlamydophila
pneumonia
legionella
pneumophila
classifi
caus
bacteria
atyp
pneumonia
respiratori
bacteria
caus
pneumonia
howev
difficult
differenti
caus
bacteria
earli
period
hospit
admiss
studi
find
major
caus
bacteria
communityacquir
pneumonia
korea
summar
tabl
legionella
especi
common
case
moder
sever
pneumonia
requir
icu
admiss
compar
atyp
pneumococc
bacteria
respiratori
viru
induc
pneumonia
children
well
communityacquir
pneumonia
adult
rapid
antigen
test
influenza
respiratori
syncyti
viru
rsv
recent
introduc
use
clinic
set
multiplex
revers
transcriptas
polymeras
chain
reaction
rtpcr
also
use
variou
respiratori
virus
recent
studi
involv
adult
communityacquir
pneumonia
multiplex
rtpcr
perform
patient
respiratori
virus
detect
patient
influenza
viru
common
n
follow
rsv
n
rhinoviru
n
coronaviru
n
adenoviru
n
metapneumoviru
n
parainfluenza
viru
n
respiratori
viru
test
perform
patient
communityacquir
pneumonia
hospit
icu
one
type
respiratori
viru
detect
patient
rtpcr
perform
rhinoviru
common
n
follow
parainfluenza
n
metapneumoviru
n
influenza
viru
n
rsv
n
coronaviru
n
adenoviru
n
caus
bacteria
atyp
pneumonia
korea
includ
mycobacterium
tuberculosi
nontubercul
mycobacteria
orientia
tsutsugamushi
leptospira
coxiella
burnetii
sinc
lenc
tuberculosi
still
quit
high
possibl
tuberculosi
one
caus
pneumonia
must
alway
consid
patient
show
delay
respons
antibiot
treatment
underli
diseas
diabet
chronic
obstruct
respiratori
diseas
chronic
kidney
diseas
longterm
steroid
use
tuberculosi
must
consid
possibl
caus
pneumonia
addit
pneumonia
caus
tuberculosi
occur
typic
bacteri
pneumonia
atyp
pneumonia
sinc
tsutsugamushi
diseas
leptospirosi
febril
ill
usual
occur
fall
sometim
accompani
atyp
pneumonia
patient
febril
ill
accompani
pneumonia
fall
pneumonia
must
differenti
possibl
febril
ill
mind
furthermor
report
pneumonia
caus
c
burnetii
korea
necessari
differenti
c
burnetii
may
possibl
caus
bacteria
pneumonia
person
come
close
direct
indirect
contact
livestock
tabl
list
common
caus
bacteria
communityacquir
pneumonia
epidemiolog
characterist
risk
factor
tabl
summar
common
clinic
characterist
associ
certain
caus
bacteria
pneumonia
isol
korea
report
highli
resist
penicillin
investig
antibacteri
resist
measur
accord
antimicrobi
suscept
test
standard
pneumonia
moder
highli
resist
penicillin
howev
expert
claim
associ
clinic
outcom
pneumonia
caus
penicillinresist
pneumonia
antibiot
resist
penicillin
anti
tabl
summar
current
antibiot
resist
pneumonia
strain
isol
korea
antibiot
resist
penicillin
ceftriaxon
report
low
erythromycin
azithromycin
still
high
antibiot
resist
fluoroquinolon
still
quit
low
gradual
increas
antibiot
resist
levofloxacin
moxifloxacin
report
respect
resist
ampicillin
due
product
common
h
influenza
domest
studi
analys
bacteri
strain
antibiot
resist
ampicillin
cefuroxim
clarithromycin
cefaclor
amoxicillin
clavulan
respect
studi
identifi
bacteri
strain
resist
levofloxacin
cefotaxim
anoth
studi
analys
bacteri
strain
antibiot
resist
ampicillin
high
cefaclor
mani
studi
analys
antibiot
suscept
pneumonia
korea
studi
examin
pneumonia
isol
respiratori
organ
sampl
pediatr
patient
gene
relat
macrolid
resist
detect
sampl
rate
report
increas
everi
year
anoth
studi
use
respiratori
organ
sampl
pediatr
patient
gene
relat
macrolid
resist
found
sampl
pneumonia
although
ratio
methicillinresist
aureu
mrsa
communityacquir
aureu
infect
increas
korea
systemat
research
role
mrsa
communityacquir
pneumonia
lack
method
respiratori
viru
test
includ
cultur
test
rapid
antigen
test
immunofluoresc
enzym
immunoassay
test
pcr
pcr
sensit
cultur
test
enzym
immunoassay
test
strength
pcr
make
advantag
adult
patient
smaller
number
nasopharyng
viru
compar
pediatr
patient
multiplex
rtpcr
use
simultan
test
variou
respiratori
virus
frequent
use
today
pcr
test
variou
respiratori
organ
sampl
includ
nasopharyng
sampl
sputum
airway
aspir
bronchoalveolar
lavag
fluid
studi
pneumonia
caus
respiratori
virus
viru
test
perform
use
sampl
upper
airway
nasal
swab
commonli
use
method
detect
virus
sensit
throat
swab
adult
patient
communityacquir
pneumonia
respiratori
virus
detect
pcr
rhinoviru
commonli
detect
respiratori
virus
influenza
metapneumoviru
rsv
parainfluenza
viru
coronaviru
also
rel
commonli
detect
howev
posit
result
upper
airway
sampl
necessarili
indic
viral
infect
posit
pcr
result
indic
pneumonia
caus
respiratori
viru
furthermor
although
respiratori
virus
induc
pneumonia
may
simpl
predispos
factor
pneumonia
therefor
possibl
bacteri
pneumonia
disregard
simpli
respiratori
bacteria
detect
pcr
test
fact
respiratori
virus
detect
patient
diagnos
bacteri
pneumonia
unclear
whether
use
antivir
agent
necessari
respiratori
virus
asid
influenza
detect
difficult
diagnos
viral
pneumonia
base
posit
result
cost
test
variou
factor
taken
consider
may
use
perform
pcr
test
detect
respiratori
virus
patient
suspect
pneumonia
caus
respiratori
virus
base
clinic
symptom
radiograph
find
wherea
legionella
urinari
antigen
test
diagnos
l
pneumophila
serogroup
pcr
diagnos
serogroup
thu
higher
sensit
legionella
diagnosi
recent
systemat
review
sensit
legionella
pcr
test
use
respiratori
organ
sampl
specif
legionella
pcr
may
perform
use
nasopharyng
sampl
nasal
swab
sputum
secret
even
induc
sputum
analysi
test
method
lower
diagnosi
rate
compar
sputum
sampl
use
variou
serolog
test
tradit
use
diagnos
mycoplasma
test
may
fail
detect
antibodi
earli
period
infect
igm
antibodi
reaction
may
occur
adult
age
year
older
mycoplasma
pcr
use
variou
respiratori
organ
sampl
higher
sensit
higher
sensit
serolog
test
similar
sensit
legionella
pcr
legionella
pcr
mycoplasma
pcr
lower
diagnosi
rate
nasopharyng
sampl
sputum
sampl
serolog
test
chlmydophila
lower
specif
compar
pcr
may
report
fals
neg
earli
period
infect
case
mycoplasma
infect
reason
pcr
may
use
serolog
test
diagnos
chlmydophila
infect
although
sensit
chlamydophila
pcr
accur
measur
chlamydophila
pcr
report
high
specif
chest
comput
tomographi
ct
accur
test
assess
parenchym
anomali
radiograph
find
indic
pneumonia
may
observ
even
anomali
observ
chest
xray
chest
ct
accur
chest
xray
diagnosi
complic
pleuriti
pulmonari
necrosi
exclus
diagnosi
differenti
diagnosi
noninfecti
lung
diseas
atelectasi
pulmonari
infarct
tumor
interstiti
lung
diseas
may
exhibit
similar
characterist
pneumonia
xray
sinc
ct
find
vari
depend
ident
caus
bacteria
pneumonia
ct
use
identifi
caus
bacteria
ct
find
suggest
mycobacteria
must
differenti
common
pneumonia
fungal
lung
infect
also
obtain
howev
due
rel
high
cost
danger
irradi
compar
chest
xray
ct
must
select
perform
case
differenti
accompani
diseas
pulmonari
embol
necessari
fungal
infect
suspect
difficult
check
lung
infiltr
chest
xray
due
underli
lung
diseas
difficult
check
pneumonia
complic
due
lack
respons
pneumonia
treatment
chest
ultrasound
use
diagnosi
variou
lung
diseas
pneumothorax
hydrothorax
pulmonari
enema
well
pneumonia
accord
recent
systemat
review
metaanalysi
use
data
patient
diagnos
pneumonia
chest
ultrasound
excel
sensit
specif
respect
diagnosi
pneumonia
compar
chest
xray
chest
ultrasound
pose
burden
radiat
exposur
perform
right
next
patient
perform
pregnant
women
accur
diagnos
lung
consolid
hydrothorax
also
use
evalu
hydrothorax
occur
complic
pneumonia
diagnos
septat
within
hydrothorax
accur
ct
septat
indic
birou
strand
pariet
viscer
pleura
well
ineffici
drainag
drainag
tube
train
examin
must
perform
ultrasound
obtain
accur
result
although
problem
interexamin
reproduc
may
aris
chest
ultrasound
may
use
diagnos
assess
pneumonia
situat
imposs
take
chest
xray
ie
difficult
transfer
patient
examin
room
patient
pregnant
immobil
adult
may
contract
communityacquir
pneumonia
test
use
identifi
caus
help
select
therapeut
antibiot
use
appropri
test
method
identifi
caus
bacteria
pneumonia
patient
diagnos
moder
sever
communityacquir
pneumonia
level
recommend
strong
level
evid
low
select
perform
test
accord
age
underli
diseas
sever
marker
epidemiolog
factor
current
histori
antibiot
use
treat
outpati
communityacquir
pneumonia
low
sever
level
recommend
strong
level
evid
low
advis
perform
blood
cultur
sputum
gram
smear
cultur
test
antibiot
administr
patient
communityacquir
pneumonia
requir
hospit
level
recommend
strong
level
evid
low
although
microbi
test
low
sensit
communityacquir
pneumonia
still
requir
reason
relat
appropri
antibiot
use
public
health
epidemiolog
import
provis
inform
caus
bacteria
within
commun
outpati
suspect
antibioticresist
bacteria
bacteria
difficult
treat
empir
use
common
antibiot
perform
sputum
gram
smear
cultur
inpati
pneumonia
recommend
perform
blood
cultur
sputum
gram
smear
cultur
test
antibiot
treatment
long
clinic
indic
patient
diagnos
moder
sever
communityacquir
pneumonia
appropri
test
method
use
identifi
caus
bacteria
pneumonia
main
reason
perform
microbi
test
communile
ms
et
al
guidelin
antibiot
use
adult
communityacquir
pneumonia
wwwicjournalorg
tyacquir
pneumonia
appropri
individu
treatment
perform
base
test
result
unnecessari
use
widespectrum
antibiot
avoid
detect
necessari
sinc
microorgan
hold
epidemiolog
signific
public
health
infect
control
also
import
obtain
inform
common
caus
microorgan
pneumonia
antibiot
sensit
howev
microbi
test
lack
sensit
often
use
earli
treatment
despit
prospect
test
diagnos
caus
microorgan
fail
detect
caus
microorgan
patient
lack
sensit
especi
patient
pneumonia
low
sever
contract
diseas
alreadi
treat
although
studi
demonstr
correl
sever
communityacquir
pneumonia
rate
blood
cultur
posit
anoth
report
correl
treat
outpati
communityacquir
pneumonia
low
sever
test
select
perform
accord
age
underli
diseas
sever
marker
epidemiolog
factor
current
histori
antibiot
use
sputum
gram
smear
cultur
may
perform
antibioticresist
bacteria
bacteria
difficult
treat
common
empir
antibiot
suspect
tuberculosi
suspect
base
clinic
radiograph
find
sputum
stain
tuberculosi
test
perform
also
recommend
perform
diagnost
test
legionella
infect
influenza
suspect
base
clinic
epidemiolog
find
inpati
pneumonia
advis
perform
blood
cultur
sputum
gram
smear
cultur
test
antibiot
administr
long
indic
sputum
test
must
done
use
sputum
sampl
obtain
antibiot
administr
perform
suffici
amount
sputum
releas
collect
transfer
treat
patient
moder
communityacquir
pneumonia
blood
cultur
legionella
pneumonia
urinari
antigen
test
sputum
gram
smear
cultur
must
perform
patient
airway
intub
test
use
transtrach
aspir
sampl
must
perform
immunodefici
patient
patient
common
treatment
fail
invas
test
airway
endoscopi
percutan
pulmonari
aspir
use
adult
may
contract
communityacquir
pneumonia
urinari
pneumonia
antigen
test
use
select
therapeut
antibiot
perform
pneumonia
urinari
antigen
test
patient
communityacquir
pneumonia
requir
hospit
level
recommend
strong
level
evid
moder
pneumonia
urinari
antigen
test
produc
result
within
minut
simpl
perform
give
posit
result
even
antibiot
administ
sensit
specif
adult
pneumonia
urinari
antigen
test
perform
patient
communityacquir
pneumonia
requir
hospit
urinari
antigen
test
pneumonia
detect
produc
result
within
minut
give
posit
result
even
antibiot
administ
report
sensit
specif
adult
drawback
test
expens
perform
assess
antibiot
suscept
also
produc
fals
posit
result
pediatr
patient
chronic
lung
diseas
character
pneumonia
colon
patient
suffer
communityacquir
pneumonia
last
four
month
test
unaffect
normal
bacteri
flora
patient
chronic
obstruct
pulmonari
diseas
posit
rate
pneumonia
urinari
antigen
test
sever
pneumonia
report
correl
patient
test
posit
pneumonia
urinari
antigen
test
posit
continu
day
treatment
begun
test
perform
use
bodili
fluid
pleural
fluid
among
studi
effect
result
pneumonia
urinari
antigen
test
treatment
retrospect
studi
report
pneumonia
caus
pneumonia
safe
effect
treat
highdos
penicillin
administr
patient
test
posit
pneumonia
urinari
antigen
test
kq
legionella
urinari
antigen
test
help
select
therapeut
antibiot
adult
may
contract
communityacquir
pneumonia
legionella
urinari
antigen
test
perform
patient
moder
sever
communityacquir
pneumonia
level
recommend
strong
level
evid
moder
legionella
urinari
antigen
test
appropri
test
method
patient
hospit
idiopath
pneumonia
recommend
case
moder
pneumonia
case
epidemiolog
evid
diseas
avail
case
respons
antibiot
legionella
urinari
antigen
test
perform
patient
moder
sever
communityacquir
pneumonia
level
recommend
strong
level
evid
moder
legionella
urinari
antigen
test
appropri
test
method
patient
hospit
idiopath
pneumonia
recommend
case
moder
pneumonia
case
epidemiolog
evid
diseas
avail
case
respons
antibiot
legionella
urinari
antigen
test
high
sensit
specif
diagnos
type
l
pneumophila
infect
test
give
posit
result
start
first
day
diseas
occur
posit
continu
sever
week
introduct
legionella
urinari
antigen
test
enabl
rapid
diagnosi
treatment
legionella
epidem
situat
improv
treatment
outcom
fatal
anoth
studi
earli
diagnosi
legionella
infect
use
legionella
urinari
antigen
test
patient
communityacquir
pneumonia
nonepidem
situat
test
result
posit
affect
treatment
seven
nine
patient
test
posit
blood
cultur
use
choos
therapeut
antibiot
adult
may
contract
communityacquir
pneumonia
blood
cultur
test
perform
antibiot
administr
patient
moder
sever
communityacquir
pneumonia
level
recommend
strong
level
evid
low
although
bacteri
detect
rate
blood
cultur
communityacquir
pneumonia
low
high
diagnost
valu
compar
cultur
test
bacteria
grow
provid
import
inform
antibiot
resist
patient
sever
communityacquir
pneumonia
immunodefici
patient
blood
cultur
test
especi
import
blood
cultur
test
perform
antibiot
administr
patient
moder
sever
communityacquir
pneumonia
pneumonia
commonli
detect
caus
bacteria
communityacquir
pneumonia
blood
cultur
test
high
diagnost
valu
compar
cultur
test
bacteria
grow
provid
import
inform
antibiot
resist
howev
low
bacteri
detect
rate
communityacquir
pneumonia
limit
influenc
treatment
even
posit
result
obtain
systemat
analysi
use
data
patient
communityacquir
pneumonia
observ
studi
blood
cultur
result
almost
effect
chang
select
empir
antibiot
even
significantli
affect
treatment
outcom
howev
sinc
immunodefici
patient
highrisk
group
exclud
analysi
result
gener
moder
communityacquir
pneumonia
overlap
predictor
blood
cultur
posit
risk
factor
sever
communityacquir
pneumonia
reason
blood
cultur
test
indic
must
perform
patient
sever
communityacquir
pneumonia
test
also
recommend
patient
immunodefici
disord
alienia
complement
defici
chronic
liver
diseas
leukopenia
hospit
criteria
pnemonia
kq
physician
must
clinic
decid
whether
patient
communityacquir
pneumonia
hospit
accord
object
criteria
level
recommend
strong
level
evid
low
use
object
criteria
unnecessari
hospit
associ
side
effect
minim
patient
requir
hospit
treat
time
manner
one
import
decis
treatment
communityacquir
pneumonia
one
hospit
hospit
patient
requir
hospit
caus
unnecessari
increas
medic
cost
treat
patient
mild
pneumonia
outpati
clinic
instead
hospit
allow
patient
return
normal
life
workplac
faster
hospit
increas
risk
thrombosi
risk
infect
pathogen
resist
bacteria
hand
treat
patient
requir
hospit
outpati
clinic
later
hospit
himher
symptom
worsen
increas
risk
death
higher
mortal
report
among
moder
communityacquir
pneumonia
treat
gener
ward
later
admit
icu
among
treat
icu
begin
therefor
import
appropri
decid
whether
patient
need
outpati
care
hospit
depend
sever
diseas
risk
death
patient
hospit
whether
hesh
treat
gener
ward
icu
rate
hospit
patient
communityacquir
pneumonia
larg
vari
hospit
physician
report
physician
gener
tend
overestim
sever
pneumonia
caus
unnecessari
hospit
one
studi
patient
lowrisk
pneumonia
admit
emerg
depart
requir
hospit
least
patient
meet
criteria
hospit
hospit
unnecessari
reason
korea
mani
patient
communityacquir
pneumonia
hospit
clear
reason
object
marker
use
clinician
predict
death
patient
communityacquir
pneumonia
sever
pneumonia
outpati
clinic
outpati
depart
medic
institut
level
hospit
emerg
depart
may
use
decid
whether
request
hospit
medic
institut
hospit
patient
psi
hospit
intens
care
unit
icu
admiss
criteria
one
lead
better
prognos
adult
may
contract
communityacquir
pneumonia
recommend
use
clinic
outpati
clinic
level
hospit
use
patient
emerg
depart
whose
blood
test
result
avail
level
recommend
strong
level
evid
low
psi
equal
predict
power
howev
psi
superior
term
applic
appropri
outpati
environ
blood
test
perform
two
marker
assess
sever
pneumonia
extens
studi
wide
use
includ
pneumonia
sever
index
develop
unit
state
use
data
pneumonia
patient
outcom
research
team
port
research
base
death
predict
model
propos
british
thorac
societi
bt
psi
score
system
develop
identifi
lowrisk
patient
among
patient
communityacquir
pneumonia
deriv
data
inpati
communityacquir
pneumonia
valid
verifi
use
data
inpati
communityacquir
pneumonia
prospect
cohort
involv
patient
tabl
psi
score
variabl
total
score
use
predict
mortal
patient
divid
five
group
predict
mortal
group
shown
tabl
gener
outpati
treatment
recommend
psi
iii
group
psi
iii
group
recommend
outpati
treatment
hospit
shortterm
monitor
depend
situat
ivv
group
recommend
hospit
pneumonia
sever
score
system
develop
use
data
prospect
collect
four
hospit
across
england
new
zealand
netherland
tabl
data
patient
includ
studi
use
guidelin
develop
remain
use
valid
indic
assign
six
score
one
point
given
satisfi
follow
condit
c
confus
u
urea
mmoll
bun
mgdl
r
respiratori
rate
b
blood
pressur
systol
pressur
mmhg
diastol
pressur
mmhg
age
year
total
result
score
rang
point
essenti
blood
urea
paramet
requir
blood
test
remov
assign
point
higher
score
higher
mortal
shown
tabl
report
par
one
anoth
term
clinic
use
discriminatori
power
howev
unclear
whether
use
pneumonia
sever
marker
improv
treatment
outcom
although
treatment
outcom
report
improv
variou
aspect
guidelin
includ
patient
characterist
sever
assess
part
hospit
decisionmak
process
psi
use
guidelin
also
consid
factor
affect
hospit
decis
also
antibiot
recommend
treatment
outcom
difficult
determin
impact
factor
hospit
decis
use
sever
marker
howev
use
object
standard
reduc
rate
hospit
among
patient
pneumonia
unclear
psi
superior
random
studi
compar
two
score
system
addit
studi
compar
predict
power
two
score
system
use
ident
patient
group
report
similar
predict
power
two
system
thu
one
say
one
superior
studi
psi
show
excel
result
accord
studi
develop
psi
particip
coresearch
psi
classifi
larger
number
patient
lowrisk
group
compar
psi
iiii
vs
similar
mortal
rate
observ
two
group
significantli
higher
predict
power
measur
term
auc
psi
howev
psi
measur
paramet
mani
blood
test
result
includ
score
calcul
work
seriou
disadvantag
outpati
emerg
depart
korea
patient
must
examin
quickli
possibl
therefor
patient
diagnos
pneumonia
first
time
outpati
depart
medic
institut
level
clinic
hospit
recommend
assess
patient
consid
transfer
anoth
hospit
accommod
inpati
hospit
whose
score
howev
outpati
treatment
may
consid
patient
satisfi
age
condit
year
older
whose
physiolog
indic
stabl
addit
case
patient
whose
blood
test
result
use
emerg
outpati
treatment
use
purpos
physician
hydrothorax
chest
xray
accompani
diseas
neoplast
diseas
within
one
year
exclud
cutan
basal
cell
carcinoma
squamou
cell
carcinoma
liver
diseas
clinic
histolog
diagnos
liver
cirrhosi
chronic
activ
hepat
congest
heart
failur
medic
histori
examin
test
cerebrovascular
diseas
stroke
diagnos
base
clinic
find
ct
mri
tabl
decis
regard
patient
need
hospit
alway
perfect
even
object
sever
score
system
high
predict
power
use
sever
score
system
mere
tool
help
clinician
make
decis
absolut
standard
replac
health
profession
clinic
decis
instanc
patient
may
place
lowrisk
group
accord
sever
score
system
may
still
requir
hospit
follow
situat
patient
develop
complic
pneumonia
patient
underli
diseas
worsen
due
pneumonia
patient
take
oral
medic
patient
place
lowrisk
group
slightli
meet
condit
classifi
highrisk
determin
patient
need
hospit
patient
social
situat
hisher
physician
must
consid
togeth
instanc
patient
advanc
age
live
alon
reduc
mobil
may
requir
hospit
hesh
recov
pneumonia
even
hisher
sever
score
low
adult
may
contract
communityacquir
pneumonia
make
icu
admiss
decis
accord
hospit
criteria
produc
good
prognos
patient
communityacquir
pneumonia
requir
mechan
ventil
septic
shock
must
hospit
icu
level
recommend
strong
level
evid
moder
patient
exhibit
ancillari
sign
sever
pneumonia
defin
idsaat
develop
pneumonia
base
clinic
find
whose
underli
diseas
worsen
need
icu
admiss
must
reassess
level
recommend
weak
level
evid
low
except
patient
requir
icu
admiss
depend
mechan
ventil
septic
shock
difficult
decid
whether
hospit
patient
accord
specif
criteria
decis
must
made
consid
variou
situat
patient
requir
mechan
ventil
septic
shock
requir
icu
admiss
although
idsaat
definit
sever
pneumonia
may
use
standard
perfect
predict
power
clinic
use
verifi
therefor
icu
admiss
decis
must
made
consid
variou
situat
tradit
accept
patient
requir
mechan
ventil
due
respiratori
failur
septic
shock
must
admit
treat
icu
howev
challeng
determin
whether
admit
patient
need
icu
communityacquir
pneumonia
guidelin
develop
atsidsa
propos
new
definit
sever
pneumonia
requir
icu
admiss
modifi
earlier
definit
propos
at
tabl
standard
consist
main
minor
standard
main
standard
includ
depend
mechan
ventil
septic
shock
requir
vasopressor
minor
standard
consist
seven
condit
includ
factor
includ
at
standard
plu
clinic
factor
patient
diagnos
sever
pneumonia
hesh
satisfi
one
condit
main
standard
three
seven
condit
minor
standard
standard
report
higher
predict
power
psi
howev
although
predict
power
standard
improv
rel
psi
minor
condit
use
exclud
patient
satisfi
main
condit
icu
admiss
standard
good
specif
moder
sensit
also
report
sinc
factor
includ
minor
standard
leukopenia
thrombocytopenia
hypothermia
rare
observ
patient
predict
power
minor
standard
chang
even
factor
exclud
ad
factor
increas
predict
power
score
system
smartcop
scap
use
predict
icu
admiss
also
similar
limit
yet
tool
use
accur
predict
patient
need
icu
care
patient
must
consid
icu
admiss
hesh
exhibit
ancillari
sign
sever
pneumonia
defin
atsidsa
pneumonia
base
clinic
sign
hisher
underli
diseas
worsen
pneumonia
treatment
outpati
kq
first
choic
antibiot
outpati
treatment
patient
may
contract
communityacquir
pneumonia
recommend
use
empir
antibiot
level
recommend
strong
level
evid
high
respiratori
fluoroquinolon
recommend
use
empir
antibiot
level
recommend
strong
level
evid
high
use
respiratori
fluoroquinolon
empir
antibiot
must
avoid
situat
tuberculosi
exclud
level
recommend
weak
level
evid
low
therapeut
effect
monotherapi
inferior
macrolid
combin
therapi
macrolid
recommend
suspect
atyp
pneumonia
respiratori
fluoroquinolon
excel
antibacteri
activ
tuberculosi
bacilli
may
thu
delay
diagnosi
tuberculosi
patient
tuberculosi
misdiagnos
anoth
kind
bacteri
pneumonia
may
allow
tuberculosi
bacilli
develop
resist
fluoroquinolon
patient
requir
hospit
use
alon
combin
use
macrolid
use
respiratori
fluoroquinolon
empir
antibiot
recommend
follow
antibiot
recommend
alphabet
order
amoxicillin
amoxicillinclavulan
cefditoren
cefpodoxim
macrolid
azithromycin
clarithromycin
roxithromycin
respiratori
fluoroquinolon
gemifloxacin
levofloxacin
moxifloxacin
macrolid
tetracyclin
monotherapi
recommend
due
high
antibiot
resist
pneumonia
macrolid
may
use
togeth
atyp
pneumonia
suspect
macrolid
azithromycin
clarithromycin
roxithromycin
recommend
controversi
regard
whether
antibiot
target
caus
bacteri
atyp
pneumonia
use
treatment
mild
communityacquir
pneumonia
requir
hospit
retrospect
studi
secondarili
conduct
use
communityacquir
pneumonia
organ
capo
databas
regist
multiinstitut
phasethre
clinic
trial
conduct
variou
countri
antibiot
effect
caus
bacteria
atyp
pneumonia
show
excel
outcom
term
mortal
rate
clinic
progress
studi
report
antibiot
treatment
caus
bacteria
atyp
pneumonia
advis
patient
communityacquir
pneumonia
term
mortal
rate
treatment
outcom
addit
idsaat
guidelin
pneumonia
treatment
develop
unit
state
also
give
recommend
howev
metaanalysi
patient
mild
communityacquir
pneumonia
use
singl
antibiot
target
caus
bacteria
atyp
pneumonia
poorer
clinic
result
use
alon
similar
result
also
report
cochran
review
patient
hospit
due
communityacquir
pneumonia
studi
publish
monotherapi
inferior
macrolid
combin
therapi
therefor
guidelin
recommend
use
macrolid
addit
case
suspect
atyp
pneumonia
classifi
penicillin
amoxicillin
amoxicillinclavulan
acid
recommend
recommend
base
research
find
pneumonia
isol
korea
low
penicillin
resist
antibacteri
suscept
standard
develop
clsi
revis
januari
stricter
criteria
penicillin
antibiot
pneumonia
patient
without
mening
use
idsaat
guidelin
bt
guidelin
ersescmid
guidelin
recommend
use
amoxicillin
main
antibiot
oral
cephalosporin
cefpodoxim
recommend
idsaat
guidelin
ersescmid
guidelin
cefditoren
recommend
ersescmid
guidelin
avail
data
regard
antibiot
suscept
caus
bacteria
pneumonia
korea
includ
guidelin
hand
cefuroxim
exclud
sinc
pneumonia
isol
korea
highli
resist
antibiot
ersescmid
guidelin
also
mention
studi
report
associ
increas
mortal
rate
cefuroxim
use
patient
pneumonia
pneumonia
accompani
bacteremia
idsaat
guidelin
bt
guidelin
ersescmid
guidelin
recommend
use
macrolid
tetracyclin
alon
howev
recommend
includ
guidelin
pneumonia
isol
korea
show
high
resist
antibiot
fluoroquinolon
monotherapi
show
excel
antibacteri
activ
tuberculosi
bacilli
reason
may
delay
diagnosi
tuberculosi
patient
communityacquir
pneumonia
whose
tuberculosi
misdiagnos
type
bacteri
pneumonia
allow
tuberculosi
bacilli
develop
resist
fluoroquinolon
therefor
case
tuberculosi
elimin
recommend
avoid
empir
use
fluoroquinolon
levofloxacin
report
oncedaili
administr
levofloxacin
mg
pharmacodynam
ideal
therapi
use
mg
levofloxacin
clinic
studi
report
oncedaili
administr
levofloxacin
mg
five
day
excel
therapeut
effect
therapi
settl
standard
method
treatment
pneumonia
sinc
studi
also
report
fiveday
gemifloxacin
therapi
inferior
sevenday
counterpart
term
therapeut
effect
gener
ward
kq
patient
may
contract
communityacquir
pneumonia
hospit
icu
macrolid
respiratori
fluoroquinolon
combin
therapi
produc
better
prognos
monotherapi
use
antibiot
respiratori
fluoroquinolon
recommend
empir
treatment
patient
mild
moder
pneumonia
admit
gener
ward
level
recommend
weak
level
evid
moder
macrolid
antibiot
may
administ
togeth
patient
suspect
atyp
bacteri
infect
patient
moder
pneumonia
limit
circumst
level
recommend
weak
level
evid
moder
signific
differ
treatment
outcom
cure
rate
side
effect
mortal
rate
etc
administr
macrolid
combin
administr
macrolid
led
higher
rate
reach
clinic
stabil
compar
administr
patient
pneumonia
caus
atyp
bacteria
sever
pneumonia
empir
antibiot
patient
admit
gener
ward
select
base
sever
diseas
word
select
base
whether
patient
mild
pneumonia
point
psi
point
moder
pneumonia
point
psi
point
sever
pneumonia
point
psi
point
empir
antibiot
method
administr
chosen
base
health
profession
judgment
patient
clinic
situat
select
antibiot
antibiot
resist
medic
allergi
complianc
previou
antibiot
use
penicillin
macrolid
fluoroquinolon
etc
cost
potenti
side
effect
isol
suscept
result
caus
bacteria
later
report
must
consid
along
clinic
progress
readjust
antibiot
select
use
respiratori
fluoroquinolon
alon
recommend
empir
treatment
mild
moder
pneumonia
idsaat
guidelin
korean
guidelin
communityacquir
pneumonia
recommend
administr
alon
conjunct
macrolid
administr
respiratori
fluoroquinolon
alon
studi
combin
antibiot
administr
includ
guidelin
either
retrospect
observ
studi
prospect
compar
studi
conduct
studi
macrolid
combin
therapi
mildmoder
pneumonia
show
differ
monotherapi
term
treatment
outcom
cure
rate
incid
side
effect
mortal
rate
etc
metaanalysi
studi
compar
therapeut
effect
macrolid
fluoroquinolon
effect
atyp
pathogen
treatment
mildmoder
pneumonia
signific
differ
clinic
progress
two
antibiot
group
rel
risk
confid
interv
prospect
capstart
studi
conduct
postma
et
al
patient
hospit
gener
ward
subject
administr
patient
macrolid
administr
patient
fluoroquinolon
administr
patient
therapeut
effect
compar
among
group
mortal
rate
group
macrolid
group
fluoroquinolon
group
therefor
treatment
outcom
observ
group
par
observ
group
studi
grain
et
al
prospect
compar
administr
macrolid
administr
treatment
patient
sever
pneumonia
patient
group
macrolid
group
reach
clinic
stabl
state
seven
day
respect
p
although
differ
rate
reach
clinic
stabil
patient
without
atyp
bacteri
infect
rel
risk
ci
pneumonia
correspond
psi
point
macrolid
group
patient
atyp
pneumonia
rel
risk
confid
interv
sever
pneumonia
correspond
psi
point
rel
risk
confid
interv
consid
rate
reach
clinic
stabil
lower
group
rate
readmiss
within
day
higher
group
p
signific
differ
clinic
marker
includ
mortal
rate
rate
icu
admiss
incid
complic
durat
hospit
stay
rate
pneumonia
recurr
two
administr
group
therefor
present
revis
guidelin
treatment
communityacquir
pneumonia
korea
recommend
administr
respiratori
fluoroquinolon
alon
patient
mildmoder
pneumonia
hospit
gener
ward
addit
consid
inpati
characterist
guidelin
recommend
intraven
inject
includ
amoxicillinclavulan
acid
ampicillinsulbactam
cefotaxim
ceftriaxon
respiratori
fluoroquinolon
includ
gemifloxacin
levofloxacin
moxifloxacin
oral
antibiot
expert
opinion
combin
administr
macrolid
recommend
treat
atyp
bacteri
infect
mycoplasma
spp
chlamydophila
spp
legionella
spp
lee
ms
et
al
guidelin
antibiot
use
adult
communityacquir
pneumonia
wwwicjournalorg
antibiot
report
reduc
mortal
rate
infect
treat
sever
pneumonia
oral
macrolid
must
use
care
associ
increas
cardiovascular
risk
patient
advanc
age
antibiot
recommend
report
low
oral
bioavail
erythromycin
increas
qt
interv
increas
cardiovascular
risk
associ
macrolid
patient
show
sever
advers
reaction
penicillin
use
respiratori
fluoroquinolon
gemifloxacin
levofloxacin
moxifloxacin
recommend
studi
report
use
fluoroquinolon
associ
delay
tuberculosi
diagnosi
increas
drug
toler
fluoroquinolon
must
use
caution
korea
preval
tuberculosi
low
prospect
random
control
clinic
report
report
therapeut
effect
moxifloxacin
monotherapi
inferior
ceftriaxon
levofloxacin
combin
therapi
also
report
similar
result
observ
group
oral
administ
gemifloxacin
anoth
administ
cefuroxim
follow
ceftriaxon
gemifloxacin
better
term
cost
adequ
durat
antibiot
treatment
patient
may
contract
communityacquir
pneumonia
antibiot
must
administ
least
five
day
level
recommend
strong
level
evid
low
antibiot
must
administ
least
five
day
adequ
durat
antibiot
administr
may
chang
depend
caus
bacteria
patient
condit
type
antibiot
treatment
respons
accompani
diseas
pneumonia
complic
statu
although
antibiot
gener
administ
day
adequ
durat
administr
period
may
chang
depend
caus
bacteria
patient
condit
type
antibiot
treatment
respons
accompani
diseas
complic
pneumonia
patient
gener
antibiot
administ
least
five
day
treatment
termin
patient
must
fever
hour
must
show
one
sign
clinic
stabl
shown
tabl
treatment
complet
studi
report
gemifloxaicn
levofloxacin
mgd
fiveday
administr
suffici
antibiot
long
halfliv
eg
azithromycin
may
use
day
case
aureu
pneumonia
accompani
bacteremia
enter
gramneg
bacilli
pneumonia
pneumonia
accompani
infect
organ
earli
treatment
failur
shortterm
antibiot
treatment
may
insuffici
patient
form
caviti
show
sign
tissu
necrosi
may
requir
longterm
treatment
legionella
pneumonia
must
treat
least
day
patient
may
contract
communityacquir
pneumonia
appropri
switch
intraven
antibiot
oral
antibiot
patient
may
switch
intraven
antibiot
oral
antibiot
hesh
clinic
stabl
take
oral
medic
level
recommend
strong
level
evid
high
patient
hospit
icu
sever
pneumonia
show
clinic
improv
hemodynam
stabl
perform
normal
oral
ingest
normal
digest
function
mayb
switch
oral
treatment
tabl
criteria
switch
oral
treatment
reduc
cough
dyspnea
fever
bodi
temperatur
last
eight
hour
normal
leukocyt
count
blood
test
suffici
oral
ingest
normal
gastrointestin
absorpt
prospect
studi
use
criteria
patient
hospit
due
pneumonia
satisfi
criteria
within
three
day
could
switch
oral
treatment
one
patient
clinic
treatment
failur
criteria
may
also
ap
pli
pneumonia
caus
pneumonia
accompani
bacteremia
known
poor
prognos
anoth
method
reduc
durat
antibiot
administr
inpati
start
oral
treatment
begin
perform
intraven
treatment
certain
period
switch
oral
treatment
latter
report
produc
treatment
outcom
exist
method
shorten
durat
hospit
stay
howev
detail
research
need
investig
patient
group
may
benefit
approach
appropri
durat
administr
necessari
monitor
hospit
patient
condit
hesh
switch
oral
antibiot
retrospect
studi
patient
advanc
age
pneumonia
differ
readmiss
rate
mortal
rate
patient
discharg
day
switch
oral
antibiot
monitor
one
day
switch
gener
recommend
use
ident
antibiot
switch
intraven
oral
treatment
antibiot
avail
recommend
use
antibiot
class
area
unit
state
rate
highlevel
macrolid
resist
low
pneumonia
oral
administr
macrolid
recommend
isol
bacteria
caus
bacteria
pneumonia
macrolid
intraven
inject
empir
antibiot
howev
area
rate
highlevel
macrolid
resist
high
pneumonia
korea
insuffici
evid
accept
principl
reason
recommend
use
oral
antibiot
class
start
intraven
antibiot
suffici
period
patient
may
contract
communityacquir
pneumonia
appropri
time
discharg
patient
undergo
oral
treatment
requir
treatment
diagnost
test
underli
diseas
social
environ
hesh
taken
care
discharg
may
consid
level
recommend
strong
level
evid
high
patient
requir
treatment
underli
diseas
requir
diagnost
test
social
environ
patient
taken
care
establish
discharg
may
consid
tabl
howev
discharg
decis
made
sole
base
object
criteria
ultim
clinician
charg
must
make
decis
consid
patient
clinic
social
situat
controversi
regard
whether
patient
must
satisfi
condit
clinic
stabil
psi
discharg
howev
condit
patient
satisfi
like
hesh
like
poor
prognos
accord
prospect
studi
monitor
inpati
pneumonia
rate
mortal
readmiss
patient
satisfi
condit
clinic
stabil
shown
tabl
last
hour
discharg
increas
odd
ratio
patient
meet
one
condit
odd
ratio
patient
satisfi
two
condit
recent
publish
prospect
studi
also
report
number
unsatisfi
condit
increas
mortal
rate
increas
fever
highli
associ
prognosi
psi
increas
time
clinic
stabil
increas
lead
longer
recoveri
time
requir
elderli
patient
variou
accompani
diseas
addit
underli
diseas
common
caus
readmiss
patient
discharg
undergo
treatment
pneumonia
therefor
determin
time
discharg
elderli
patient
variou
underli
diseas
advis
assess
whether
tabl
criteria
switch
oral
antibiot
patient
satisfi
criteria
clinic
stabil
shown
tabl
pneumonia
without
bacteremia
etiolog
pneumonia
legionella
spp
staphylococcu
aureu
enterobacteriacea
normal
gastrointestin
absorpt
kq
patient
may
contract
communityacquir
pneumonia
oxygen
therapi
lowmolecularweight
heparin
therapi
earli
ambul
help
level
oxygen
maintain
via
oxygen
therapi
patient
hypoxemia
level
recommend
weak
level
evid
low
lowmolecularweight
heparin
inject
patient
high
risk
venou
thromboembol
level
recommend
strong
level
evid
high
earli
ambul
recommend
level
recommend
strong
level
evid
high
oxygen
therapi
high
concentr
oxygen
may
safe
appli
patient
requir
oxygen
therapi
maintain
arteri
partial
oxygen
pressur
kpa
oxygen
satur
level
risk
hypercapn
respiratori
failur
high
patient
high
risk
hypercapn
respiratori
failur
treatment
must
begin
low
concentr
oxygen
therapi
follow
oxygen
infus
oxygen
satur
maintain
ph
arteri
blood
ga
test
result
repeatedli
check
lowmolecularweight
heparin
therapi
patient
pneumonia
accompani
acut
respiratori
failur
classifi
highrisk
group
must
administ
lowmolecularweight
heparin
administr
appropri
antibiot
appropri
time
use
guidelin
heparin
administr
prevent
thromboembol
observ
reduc
mortal
rate
earli
ambul
earli
ambul
show
good
clinic
prognos
prospect
studi
involv
subject
durat
hospit
stay
shorter
day
patient
came
bed
maintain
upright
postur
least
minut
first
hour
hospit
admiss
gradual
increas
level
physic
activ
kq
patient
may
contract
communityacquir
pneumonia
admit
icu
treatment
respiratori
fluoroquinolon
combin
therapi
lead
better
prognos
monotherapi
patient
requir
icu
admiss
azithromycinfluoroquinolon
combin
therapi
recommend
monotherapi
level
recommend
strong
level
evid
moder
patient
may
contract
communityacquir
pneumonia
admit
icu
treatment
respiratori
fluoroquinolon
combin
therapi
lead
better
prognos
respiratori
fluoroquinolon
monotherapi
patient
requir
icu
admiss
azithromycinfluoroquinolon
combin
therapi
recommend
monotherapi
level
recommend
strong
level
evid
moder
patient
requir
icu
admiss
azithromycinfluoroquinolon
combin
therapi
recommend
respiratori
fluoroquinolon
monotherapi
level
recommend
strong
level
evid
moder
patient
communityacquir
pneumonia
requir
icu
admiss
combin
therapi
recommend
monotherapi
pneumonia
caus
p
aeruginosa
suspect
combin
therapi
use
two
antibiot
antipseudomon
effect
perform
prevent
inappropri
treatment
communityacquir
pneumonia
caus
mrsa
suspect
vancomycin
teicoplanin
linezolid
may
use
clindamycin
rifampin
may
ad
mani
domest
clinic
studi
caus
bacteria
antibiot
treatment
sever
communityacquir
pneumonia
accord
foreign
research
pneumonia
legionella
spp
h
influenza
enterbacteriacea
spp
aureu
pseudomona
spp
major
caus
bacteria
communityacquir
pneumonia
case
communityacquir
pneumonia
due
atyp
bacteria
legionella
especi
import
sever
pneumonia
caus
atyp
bacteria
antibiot
antibacteri
activ
bacteria
must
includ
earli
empir
treatment
clinic
studi
conduct
date
combin
therapi
benefici
monotherapi
treat
mild
pneumonia
howev
combin
therapi
produc
better
result
patient
sever
pneumonia
azithromycin
b
fluoroquinolon
combin
therapi
perform
follow
antibiot
recommend
alphabet
order
ampicillinsulbactam
cefotaxim
ceftriaxon
macrolid
azithromycin
respiratori
fluoroquinolon
gemifloxacin
levofloxacin
moxifloxacin
respiratori
fluoroquinolon
aztreonam
recommend
patient
hypersensit
penicillin
random
control
clinic
trial
involv
patient
communityacquir
pneumonia
accompani
shock
combin
therapi
signific
effect
howev
combin
therapi
show
better
outcom
fluoroquinolon
monotherapi
patient
mechan
ventil
anoth
retrospect
studi
macrolid
combin
therapi
led
higher
surviv
rate
fluoroquinolon
monotherapi
patient
sever
pneumonia
patient
admit
icu
experi
shock
requir
mechan
ventil
therefor
combin
therapi
recommend
fluoroquinolon
monotherapi
patient
effect
fluoroquinolon
monotherapi
pneumonia
accompani
mening
caus
pneumonia
unclear
recent
noninferior
trial
macrolid
combin
therapi
produc
better
outcom
monotherapi
sever
pneumonia
pneumonia
caus
atyp
bacteria
prospect
observ
studi
involv
patient
pneumonia
bacteremia
combin
therapi
macrolid
fluoroquinolon
also
led
higher
surviv
rate
compar
monotherapi
result
observ
patient
mild
pneumonia
patient
sever
pneumonia
studi
also
report
better
treatment
outcom
combin
therapi
monotherapi
even
patient
treat
effect
antibiot
therefor
empir
antibiot
treatment
patient
sever
communityacquir
pneumonia
requir
icu
admiss
combin
therapi
recommend
monotherapi
follow
combin
therapi
may
perform
antipneumococc
antipseudomon
cefepim
piperacillintazobactam
imipenem
meropenem
may
use
antipneumococc
antipseudomon
ciprofloxacin
levofloxacin
b
antipneumococc
antipseudomon
aminoglycosid
azithromycin
c
antipneumococc
antipseudomon
aminoglycosid
antipneumococc
fluoroquinolon
gemifloxacin
levofloxacin
moxifloxacin
risk
factor
p
aeruginosa
infect
includ
alcohol
consumpt
structur
lung
diseas
bronchodil
frequent
use
steroid
due
acut
worsen
chronic
obstruct
pulmonari
diseas
use
antibiot
last
three
month
possibl
patient
pneumonia
caus
p
aeruginosa
antibiot
effect
highli
sensit
pneumonia
must
select
exampl
antibiot
includ
cefepim
piperacillintazobactam
imipenem
meropenem
prospect
observ
studi
gramneg
bacillu
infect
includ
caus
p
aeruginosa
associ
high
mortal
rate
multiinstitut
studi
conduct
asian
gramneg
bacilli
account
case
death
common
caus
bacteria
sever
pneumonia
risk
factor
death
bacteria
p
aeruginosa
may
exhibit
variou
level
antibiot
resist
therefor
two
empir
combin
therapi
need
bacteria
recommend
readjust
antibiot
select
bacteria
isol
suscept
result
obtain
although
communityacquir
mrsa
usual
detect
skin
soft
tissu
infect
rare
caus
sever
communityacquir
pneumonia
occur
healthi
adult
associ
common
risk
factor
hospitalacquir
infect
report
occur
associ
new
influenza
virus
produc
pantonvalentin
leucocidin
pvl
toxin
caus
necrot
pneumonia
associ
high
mortal
rate
unlik
case
hospitalacquir
mrsa
communityacquir
mrsa
may
suscept
sulfamethoxazol
tmpsmx
clindamycin
vancomycin
reduc
toxin
product
yet
clear
tmpsmx
fluoroquinolon
reduc
toxin
product
although
establish
method
treatment
clindamycin
reduc
toxin
product
rifampin
bactericid
activ
aureu
may
use
among
novel
antibiot
daptomycin
effect
soft
tissu
infect
caus
mrsa
bacteremia
howev
effect
may
reduc
due
surfact
lung
therefor
recommend
enough
evid
regard
effect
tigecyclin
pneumonia
patient
may
contract
communityacquir
pneumonia
admit
icu
treatment
treatment
legionella
lead
better
prognos
patient
sever
communityacquir
pneumonia
requir
icu
admiss
necessari
perform
treatment
legionella
level
recommend
strong
level
evid
low
communityacquir
pneumonia
caus
legionella
often
sever
treatment
bacteria
must
includ
empir
antibiot
treatment
patient
admit
icu
must
subject
treatment
pneumoniea
legionella
spp
accord
foreign
studi
infect
caus
atyp
bacteria
account
case
sever
communityacquir
pneumonia
legionella
play
main
role
domest
studi
legionella
account
caus
bacteria
pneumonia
common
compar
atyp
pathogen
patient
sever
pneumonia
requir
icu
admiss
patient
may
contract
communityacquir
pneumonia
admit
icu
treatment
steroid
therapi
lead
good
prognos
steroid
therapi
may
consid
patient
sever
communityacquir
pneumonia
accompani
shock
level
recommend
weak
level
evid
low
although
use
steroid
treat
sever
communityacquir
pneumonia
shorten
time
reach
clinic
stabil
studi
lead
chang
mortal
rate
howev
studi
involv
patient
septic
shock
adren
insuffici
steroid
use
lead
decreas
mortal
rate
studi
result
regard
use
steroid
sever
communityacquir
pneumonia
vari
greatli
recentlyconduct
largescal
studi
use
steroid
addit
pneumonia
treatment
led
faster
bacteriolog
convers
shorten
time
clinic
stabil
shorten
durat
hospit
stay
smallscal
random
studi
involv
patient
admit
icu
sevenday
use
hydrocortison
reduc
durat
hospit
stay
mortal
rate
two
smallscal
studi
use
steroid
produc
better
treatment
outcom
oppos
use
howev
studi
small
scale
differ
characterist
patient
group
rel
recent
conduct
random
control
studi
durat
hospit
stay
reduc
day
steroid
group
differ
mortal
rate
observ
addit
steroid
addit
use
patient
pneumonia
signific
differ
symptom
improv
overal
cure
rate
complic
rate
icu
admiss
mortal
rate
observ
compar
group
subject
steroid
administr
rate
hyperglycemia
side
effect
higher
steroid
group
howev
random
control
studi
involv
patient
septic
shock
sevenday
use
lowdos
hydrocortison
reduc
mortal
rate
patient
hypoadren
reduc
mortal
rate
number
day
mechan
ventil
patient
acut
respiratori
failur
addit
hypoadren
therefor
patient
sever
communityacquir
pneumonia
accompani
shock
requir
vasopressor
use
steroid
may
consid
patient
communityacquir
pneumonia
show
clear
symptom
improv
high
risk
lung
cancer
recommend
take
followup
chest
xray
examin
treatment
respons
level
recommend
strong
level
evid
low
lesion
improv
manifest
slowli
clinic
symptom
chestxray
patient
pneumonia
lesion
loss
may
radiolog
manifest
slowli
even
week
treatment
patient
age
year
older
multilobar
pneumonia
underli
diseas
patient
age
year
older
male
smoker
chest
xray
must
perform
differenti
underli
lung
diseas
pneumonia
week
treatment
confirm
complet
lesion
loss
gener
radiolog
anomali
pneumonia
manifest
slowli
clinic
symptom
studi
prospect
observ
inpati
sever
pneumonia
patient
show
clinic
improv
seven
day
radiolog
show
improv
day
patient
complet
recov
base
clinic
find
complet
lesion
loss
base
chest
xray
studi
monitor
chest
xray
patient
communityacquir
pneumonia
emerg
outpati
depart
week
patient
complet
lesion
loss
two
week
complet
lesion
loss
four
week
radiolog
improv
usual
observ
slowli
multilobar
pneumonia
rate
improv
chest
xray
chang
depend
patient
age
underli
lung
diseas
patient
year
old
younger
underli
lung
diseas
show
lesion
improv
chest
xray
within
four
week
howev
patient
year
older
underli
lung
diseas
may
show
radiolog
improv
week
addit
treatment
outcom
pneumonia
associ
sign
worsen
chest
xray
taken
followup
period
therefor
repeatedli
take
chest
xray
patient
pneumonia
shown
clinic
improv
may
addit
benefit
howev
necessari
take
followup
chest
xray
elimin
possibl
underli
diseas
pneumonia
patient
year
old
older
male
smoker
largescal
cohort
studi
involv
patient
patient
diagnos
communityacquir
pneumonia
newli
diagnos
pneumonia
within
day
age
year
older
adjust
hr
ci
male
gender
adjust
hr
ci
smoke
adjust
hr
ci
signific
risk
factor
pneumonia
patient
communityacquir
pneumonia
diagnos
pneumonia
high
proport
patient
age
year
older
therefor
necessari
take
followup
chest
xray
patient
communityacquir
pneumonia
addit
elimin
possibl
pneumonia
underli
diseas
patient
show
suffici
clinic
improv
week
treatment
chest
xray
may
repeatedli
obtain
patient
may
contract
communityacquir
pneumonia
creactiv
protein
crp
test
use
assess
therapeut
effect
crp
level
may
repeatedli
measur
assess
risk
treatment
failur
complic
patient
clinic
show
clear
symptom
improv
level
recommend
weak
level
evid
low
repeat
crp
measur
three
four
day
treatment
help
identifi
patient
risk
treatment
failur
increas
risk
complic
patient
whose
crp
decreas
four
day
treatment
tend
higher
mortal
rate
higher
risk
ventil
vasopressor
use
risk
complic
pneumonia
pyothorax
base
find
prospect
studi
ana
lyze
inpati
communityacquir
pneumonia
repeat
crp
measur
three
four
day
treatment
help
identifi
patient
risk
treatment
failur
increas
risk
complic
crp
level
mgdl
four
day
treatment
significantli
associ
incid
complic
hand
patient
crp
level
mgdl
three
day
treatment
low
risk
complic
addit
patient
whose
crp
level
decreas
four
day
treatment
higher
mortal
rate
higher
risk
ventil
vasopressor
use
higher
risk
complic
pneumonia
pyothorax
therefor
although
repeat
crp
measur
significantli
benefici
clinic
aspect
patient
whose
symptom
worsen
crp
monitor
may
help
identifi
patient
risk
treatment
failur
complic
among
show
clear
sign
clinic
improv
worsen
earli
period
hospit
patient
may
contract
communityacquir
pneumonia
procalcitonin
test
use
assess
therapeut
effect
procalcitonin
test
may
use
process
decid
whether
continu
antibiot
treatment
patient
show
clinic
improv
level
evid
moder
level
recommend
weak
repeat
procalcitonin
measur
may
use
auxiliari
method
predict
prognos
patient
pneumonia
antibiot
use
cessat
antibiot
use
base
procalcitonin
level
help
reduc
dose
durat
antibiot
use
without
increas
risk
treatment
failur
complic
repeat
procalcitonin
measur
may
help
predict
patient
prognosi
procalcitonin
level
patient
admit
icu
due
sever
communityacquir
pneumonia
measur
one
three
day
hospit
increas
procalcitonin
level
three
day
identifi
signific
prognost
factor
indic
poor
prognos
anoth
studi
patient
hospit
due
communityacquir
pneumonia
clinic
stabil
within
hour
whose
procalcitonin
level
repeatedli
measur
hour
ngml
develop
seriou
complic
procalcitonin
crp
mild
region
proatrial
natriuret
peptid
mr
proanp
level
continu
measur
patient
pneumonia
high
level
mr
proanp
procalcitonin
level
consist
observ
patient
develop
complic
die
numer
random
control
clinic
studi
conduct
determin
whether
procalcitonin
use
criteria
begin
ceas
antibiot
use
accord
metaanalysi
analys
patient
differ
acut
respiratori
infect
use
procalcitonin
criteria
antibiot
use
lead
signific
differ
risk
treatment
failur
mortal
rate
compar
exist
treatment
guidelin
use
significantli
reduc
number
day
antibiot
use
metaanalysi
analys
patient
communityacquir
pneumonia
separ
signific
differ
mortal
rate
procalcitonin
control
group
respect
adjust
odd
ratio
ci
howev
rate
treatment
failur
lower
procalcitonin
group
compar
exist
treatment
group
respect
adjust
ci
p
median
number
day
antibiot
use
decreas
day
day
p
prospect
multiinstitut
random
control
clinic
studi
recent
publish
find
regard
use
procalcitonin
test
criteria
cessat
antibiot
use
patient
administ
antibiot
within
hour
icu
admiss
due
infect
patient
includ
studi
communityacquir
pneumonia
procalcitonin
group
cessat
antibiot
use
recommend
procalcitonin
level
decreas
rel
level
time
admiss
level
consist
previou
studi
dose
antibiot
use
durat
antibiot
use
significantli
decreas
procalcitonin
group
compar
control
group
mortal
rate
day
decreas
p
oneyear
mortal
rate
decreas
p
procalcitonin
group
compar
control
group
howev
studi
publish
europ
patient
group
includ
studi
heterogen
term
diseas
addit
ratio
patient
procalcitonin
group
vari
depend
research
http
infect
chemoth
wwwicjournalorg
algorithm
studi
need
investig
costeffect
procalcitonin
test
reduc
cost
antibiot
prescript
yet
earli
recommend
antibiot
treatment
accord
procalcitonin
test
result
actual
clinic
practic
guidelin
polysaccharid
pneumococc
vaccin
recent
shown
prevent
invas
pneumococc
diseas
patient
advanc
age
risk
factor
pneumonia
infect
protein
conjug
pneumococc
vaccin
recent
shown
prevent
pneumonia
invas
pneumococc
diseas
patient
advanc
age
patient
risk
factor
pneumonia
infect
combin
inject
protein
conjug
polysaccharid
pneumococc
vaccin
recommend
risk
factor
invas
pneumococc
diseas
caus
includ
age
year
older
resid
longterm
care
facil
dementia
convuls
diseas
congest
heart
failur
cardiovascular
diseas
chronic
obstruct
pulmonari
diseas
previou
histori
pneumonia
chronic
liver
diseas
diabet
alienia
chronic
cerebrospin
fluid
leakag
accord
previou
literatur
polysaccharid
pneumococc
vaccin
prevent
invas
pneumococc
diseas
older
adult
age
year
older
effect
slightli
reduc
patient
chronic
diseas
numer
cohort
studi
recent
demonstr
vaccin
reduc
incid
pneumonia
pneumococc
pneumonia
hospit
due
pneumonia
death
pneumonia
howev
report
vaccin
prevent
effect
pneumonia
hospit
due
pneumonia
patient
asplenia
advanc
age
highrisk
group
must
revaccin
five
year
safeti
immunogen
vaccin
verifi
numer
studi
recent
largescal
studi
protein
conjug
pneumococc
vaccin
prevent
pneumococc
pneumonia
invas
pneumococc
diseas
howev
vaccin
prevent
effect
type
pneumonia
prevent
effect
polysaccharid
pneumococc
vaccin
invas
pneumococc
diseas
well
protein
conjug
pneumococc
vaccin
pneumococc
infect
verifi
accordingli
domest
pneumococc
vaccin
guidelin
recommend
perform
combin
inject
protein
conjug
polysaccharid
vaccin
patient
advanc
age
risk
factor
pneumococc
infect
smoke
cessat
educ
prevent
communityacquir
pneumonia
among
adult
contract
communityacquir
pneumonia
smoke
cessat
educ
necessari
current
smoker
pneumonia
level
recommend
strong
level
evid
high
smoke
import
risk
factor
pneumonia
even
healthi
adult
therefor
smoke
cessat
import
prevent
pneumonia
smoke
known
risk
factor
invas
pneumococc
diseas
even
young
peopl
immunosuppress
direct
indirect
smoke
risk
factor
communityacquir
pneumonia
addit
smoke
risk
factor
legionella
infect
smoke
cessat
educ
need
prevent
pneumonia
smoker
hospit
due
pneumonia
educ
must
begin
hospit
